Health Care [ 4/12 ] | Biotechnology [ 18/74 ]
NASDAQ | Common Stock
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
It operates in two segments, Shared R&D and Just " Evotec Biologics.
The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio-metabolic disorders; and animal and women health.
It has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore, as well as partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.
Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -0.12 Increased by 0.00% | -0.08 Decreased by -50.00% |
| Aug 14, 24 | -0.29 Decreased by -620.50% | -0.06 Decreased by -380.33% |
| May 22, 24 | -0.06 Increased by +25.00% | -0.10 Increased by +40.00% |
| Feb 26, 24 | -0.05 Increased by +61.54% | -0.03 Decreased by -66.67% |
| Nov 8, 23 | -0.12 Increased by +12.73% | -0.05 Decreased by -140.00% |
| Aug 29, 23 | -0.04 Increased by +50.00% | -0.04 |
| May 12, 23 | -0.08 Increased by +65.22% | 0.10 Decreased by -180.00% |
| Mar 29, 23 | -0.13 Decreased by -18.18% | 0.10 Decreased by -230.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 184.89 M Decreased by -5.80% | -39.63 M Decreased by -1.74% | Decreased by -21.44% Decreased by -8.01% |
| Jun 30, 24 | 182.12 M Decreased by -7.21% | -94.93 M Decreased by -143.70% | Decreased by -52.13% Decreased by -162.64% |
| Mar 31, 24 | 208.73 M Decreased by -13.28% | -20.67 M Increased by +24.00% | Decreased by -9.90% Increased by +12.36% |
| Dec 31, 23 | 201.31 M Decreased by -16.36% | -16.13 M Increased by +40.70% | Decreased by -8.01% Increased by +29.10% |
| Sep 30, 23 | 196.28 M Increased by +12.88% | -38.95 M Increased by +17.60% | Decreased by -19.85% Increased by +27.00% |
| Jun 30, 23 | 196.28 M Increased by +13.98% | -38.95 M Decreased by -39.44% | Decreased by -19.85% Decreased by -22.34% |
| Mar 31, 23 | 240.69 M Increased by +28.66% | -27.20 M Increased by +13.59% | Decreased by -11.30% Increased by +32.84% |
| Dec 31, 22 | 240.69 M Increased by +28.66% | -27.20 M Increased by +13.59% | Decreased by -11.30% Increased by +32.84% |